JP6968696B2 - 異常なレベル及び／又は活性のｉｆｐ３５ファミリーのタンパク質に関連する疾患又は障害を治療及び／又は予防するための方法及び組成物 - Google Patents

異常なレベル及び／又は活性のｉｆｐ３５ファミリーのタンパク質に関連する疾患又は障害を治療及び／又は予防するための方法及び組成物 Download PDF

Info

Publication number
JP6968696B2
JP6968696B2 JP2017510624A JP2017510624A JP6968696B2 JP 6968696 B2 JP6968696 B2 JP 6968696B2 JP 2017510624 A JP2017510624 A JP 2017510624A JP 2017510624 A JP2017510624 A JP 2017510624A JP 6968696 B2 JP6968696 B2 JP 6968696B2
Authority
JP
Japan
Prior art keywords
ifp35
nmi
nid
antibody
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017510624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528129A5 (enExample
JP2017528129A (ja
Inventor
インファン・リウ
ヂーファ・リウ
ファンファン・リャン
ジュエン・シェン
ルイチン・イェン
ヂーカイ・シァホウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2017528129A publication Critical patent/JP2017528129A/ja
Publication of JP2017528129A5 publication Critical patent/JP2017528129A5/ja
Application granted granted Critical
Publication of JP6968696B2 publication Critical patent/JP6968696B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
JP2017510624A 2014-08-22 2015-08-21 異常なレベル及び／又は活性のｉｆｐ３５ファミリーのタンパク質に関連する疾患又は障害を治療及び／又は予防するための方法及び組成物 Active JP6968696B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410418773.1 2014-08-22
CN201410418773 2014-08-22
PCT/CN2015/000602 WO2016026258A1 (en) 2014-08-22 2015-08-21 Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins

Publications (3)

Publication Number Publication Date
JP2017528129A JP2017528129A (ja) 2017-09-28
JP2017528129A5 JP2017528129A5 (enExample) 2018-10-04
JP6968696B2 true JP6968696B2 (ja) 2021-11-17

Family

ID=55350147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017510624A Active JP6968696B2 (ja) 2014-08-22 2015-08-21 異常なレベル及び／又は活性のｉｆｐ３５ファミリーのタンパク質に関連する疾患又は障害を治療及び／又は予防するための方法及び組成物

Country Status (5)

Country Link
US (4) US11466061B2 (enExample)
EP (1) EP3182990A4 (enExample)
JP (1) JP6968696B2 (enExample)
CN (3) CN115054687A (enExample)
WO (1) WO2016026258A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115054687A (zh) 2014-08-22 2022-09-16 广州英恩迈生物医药科技有限公司 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
US12473352B2 (en) * 2019-04-01 2025-11-18 Guangzhou Enmai Biotechnology Co., Ltd. Diagnosis and treatment for chronic inflammation and virus infection
CN110669765B (zh) * 2019-11-04 2022-11-01 中国科学院水生生物研究所 鳜干扰素诱导蛋白启动子和应用
CN113234153B (zh) * 2021-04-07 2022-12-20 中山大学 一批识别ifp35家族蛋白的单克隆抗体及其在免疫识别等方面的应用
CN118562950A (zh) * 2021-07-09 2024-08-30 广州恩迈生物科技有限公司 Ifp35和/或nmi在诊治系统性红斑狼疮中的应用
CN116239685A (zh) * 2023-02-24 2023-06-09 中山大学·深圳 一种识别ifp35蛋白的抗体及其应用
KR20250162870A (ko) * 2023-04-10 2025-11-19 광저우 언마이 바이오테크놀로지 컴퍼니 리미티드 항-nmi 단클론 항체 또는 이의 항원 결합 단편 및 이의 응용
CN120536560A (zh) * 2024-02-19 2025-08-26 中山大学·深圳 Ifp35家族蛋白在诊断脓毒症或其相关疾病中的应用
CN120847414A (zh) * 2025-06-04 2025-10-28 浙江大学 Nmi蛋白作为生物标志物在成人脓毒症严重程度及预后评估中的应用
CN120842381B (zh) * 2025-07-22 2026-06-02 中山大学 一种识别nmi蛋白的单克隆抗体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050406A1 (en) * 1997-05-09 1998-11-12 The General Hospital Corporation Cell proliferation related genes
EP0921192A1 (en) * 1997-12-03 1999-06-09 Leadd B.V. Molecules interacting with apoptin
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
AU2005334466B2 (en) * 2004-11-05 2011-05-26 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Diagnosis and prognosis of infectious disease clinical phenotypes and other physiologic states using host gene expression biomarkers in blood
US20090136506A1 (en) * 2005-10-03 2009-05-28 Mark Bittinger Conserved Membrane Activator of Calcineurin (CMAC), a Novel Therapeutic Protein and Target
FR2892730A1 (fr) * 2005-10-28 2007-05-04 Biomerieux Sa Methode pour detecter la presence ou le risque de developper un cancer
CN101473045B (zh) * 2006-04-24 2016-08-03 健泰科生物技术公司 用于检测自身免疫性病症的方法和组合物
KR20090023360A (ko) * 2006-04-26 2009-03-04 버텍스 파마슈티칼스 인코포레이티드 Ｃ형 간염 바이러스 감염 바이오마커
KR101326367B1 (ko) * 2006-07-03 2013-11-11 가톨릭대학교 산학협력단 항암제 저항성의 진단 방법 및 진단 키트
SG177956A1 (en) * 2006-08-11 2012-02-28 Baylor Res Inst Gene expression signatures in blood leukocytes permit differential diagnosis of acute infections
US20100093611A1 (en) * 2007-05-16 2010-04-15 Horrigan Stephen K Compounds and methods for treating or preventing autoimmune diseases
CN115054687A (zh) 2014-08-22 2022-09-16 广州英恩迈生物医药科技有限公司 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
US12473352B2 (en) 2019-04-01 2025-11-18 Guangzhou Enmai Biotechnology Co., Ltd. Diagnosis and treatment for chronic inflammation and virus infection

Also Published As

Publication number Publication date
CN107427552B (zh) 2022-12-20
CN115054687A (zh) 2022-09-16
CN114796497A (zh) 2022-07-29
US11466061B2 (en) 2022-10-11
WO2016026258A1 (en) 2016-02-25
EP3182990A4 (en) 2018-04-11
US20230265135A1 (en) 2023-08-24
EP3182990A1 (en) 2017-06-28
US20250059242A1 (en) 2025-02-20
US20180037617A1 (en) 2018-02-08
CN107427552A (zh) 2017-12-01
JP2017528129A (ja) 2017-09-28
US12655183B2 (en) 2026-06-16
US20250084137A1 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
US20250084137A1 (en) Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins
EP4283295A2 (en) Recombinant polyclonal proteins and methods of use thereof
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP7558949B2 (ja) 抗ｃｔｌａ－４結合タンパク質およびその使用方法
WO2020140094A1 (en) Anti-b7-h3 binding proteins and methods of use thereof
CN113544146A (zh) 抗pd-1结合蛋白及其使用方法
BR112014006175B1 (pt) Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
CN105431455A (zh) 抗激活素a化合物对受试者的施用
CN114787181A (zh) 用抗pd-1/il-15免疫细胞因子靶向pd-1的新型免疫疗法
WO2020142626A1 (en) Anti-ox40 binding proteins and methods of use thereof
KR20190017869A (ko) 엔테로바이러스 71에 대한 인간화 항체
WO2020140070A1 (en) Anti-b7-h4 binding proteins and methods of use thereof
WO2020140090A1 (en) Anti-pd-l1 binding proteins and methods of use thereof
WO2023187383A1 (en) Virus-like particles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180821

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210915

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211027

R150 Certificate of patent or registration of utility model

Ref document number: 6968696

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250